Cytokine Signalling Forum

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Informações:

Sinopsis

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’